Current Oncology Reports

, Volume 11, Issue 2, pp 94–101 | Cite as

VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy

  • C. Lance Cowey
  • W. Kimryn RathmellEmail author


The therapeutic landscape for renal cell carcinoma (RCC) has changed drastically over the past several years with the emergence of molecularly targeted therapies. With previous prognostic and predictive tools based on studies of patients treated with cytokine therapies, confirmation of these prior methods and discovery of new markers in this new era of targeted therapy are of great importance. Alteration of the von Hippel-Lindau gene (VHL) by mutation, loss of heterozygosity, and promoter methylation has been found to be important to RCC pathogenesis. In this review, we discuss the potential role of VHL mutation as a prognostic and predictive marker for RCC.


Vascular Endothelial Growth Factor Renal Cell Carcinoma Sorafenib Axitinib Clear Cell Renal Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71–96.PubMedCrossRefGoogle Scholar
  2. 2.
    Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417.PubMedCrossRefGoogle Scholar
  3. 3.
    Bukowski RM: Cytokine therapy for metastatic renal cell carcinoma. Semin Urol Oncol 2001, 19:148–154.PubMedGoogle Scholar
  4. 4.
    Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999, 17:2530–2540.PubMedGoogle Scholar
  5. 5.
    Cowey C, Rathmell WK: Using molecular biology to develop drugs for renal cell carcinoma. Expert Opin Drug Discov 2008, 3:311–327.CrossRefGoogle Scholar
  6. 6.
    Kaelin WG Jr: The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 2007, 13(2 Pt 2):680s–684s.PubMedCrossRefGoogle Scholar
  7. 7.
    Motzer RJ, Hutson TE, Tomczak P, et al.: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115–124.PubMedCrossRefGoogle Scholar
  8. 8.
    Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125–134.PubMedCrossRefGoogle Scholar
  9. 9.
    Hudes G, Carducci M, Tomczak P, et al.: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356:2271–2281.PubMedCrossRefGoogle Scholar
  10. 10.
    Lonser RR, Glenn GM, Walther M, et al.: von Hippel-Lindau disease. Lancet 2003, 361:2059–2067.PubMedCrossRefGoogle Scholar
  11. 11.
    Latif F, Tory K, Gnarra J, et al.: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260:1317–1320.PubMedCrossRefGoogle Scholar
  12. 12.
    Iliopoulos O, Levy AP, Jiang C, et al.: Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996, 93:10595–10599.PubMedCrossRefGoogle Scholar
  13. 13.
    Iwai K, Yamanaka K, Kamura T, et al.: Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc Natl Acad Sci U S A 1999, 96:12436–12441.PubMedCrossRefGoogle Scholar
  14. 14.
    Maxwell PH, Wiesener MS, Chang GW, et al.: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271–275.PubMedCrossRefGoogle Scholar
  15. 15.
    Wiesener MS, Munchenhagen PM, Berger I, et al.: Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001, 61:5215–5222.PubMedGoogle Scholar
  16. 16.
    Iliopoulos O, Kibel A, Gray S, et al.: Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995, 1:822–826.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen F, Kishida T, Duh FM, et al.: Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995, 55:4804–4807.PubMedGoogle Scholar
  18. 18.
    Zbar B, Kishida T, Chen F, et al.: Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996, 8:348–357.PubMedCrossRefGoogle Scholar
  19. 19.
    Friedrich CA: Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum Mol Genet 2001, 10:763–767.PubMedCrossRefGoogle Scholar
  20. 20.
    Hacker KE, Lee CM, Rathmell WK: VHL type 2B mutations retain VBC form and function. PLoS ONE 2008, 3:e3801.PubMedCrossRefGoogle Scholar
  21. 21.
    Li L, Zhang L, Zhang X, et al.: Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 2007, 27:5381–5392.PubMedCrossRefGoogle Scholar
  22. 22.
    Foster K, Prowse A, van den Berg A, et al.: Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994, 3:2169–2173.PubMedCrossRefGoogle Scholar
  23. 23.
    Gnarra JR, Tory K, Weng Y, et al.: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994, 7:85–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Shuin T, Kondo K, Torigoe S, et al.: Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994, 54:2852–2855.PubMedGoogle Scholar
  25. 25.
    Nickerson ML, Jaeger E, Shi Y, et al.: Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res 2008, 14:4726–4734.PubMedCrossRefGoogle Scholar
  26. 26.
    Herman JG, Latif F, Weng Y, et al.: Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91:9700–9704.PubMedCrossRefGoogle Scholar
  27. 27.
    Clifford SC, Prowse AH, Affara NA, et al.: Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998, 22:200–209.PubMedCrossRefGoogle Scholar
  28. 28.
    Dulaimi E, Ibanez de Caceres I, Uzzo RG, et al.: Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004, 10(12 Pt 1):3972–3979.PubMedCrossRefGoogle Scholar
  29. 29.
    Brauch H, Weirich G, Brieger J, et al.: VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000, 60:1942–1948.PubMedGoogle Scholar
  30. 30.
    Schraml P, Struckmann K, Hatz F, et al.: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196:186–193.PubMedCrossRefGoogle Scholar
  31. 31.
    Patard JJ, Fergelot P, Karakiewicz PI, et al.: Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer 2008, 123:395–400.PubMedCrossRefGoogle Scholar
  32. 32.
    Yao M, Yoshida M, Kishida T, et al.: VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002, 94:1569–1575.PubMedGoogle Scholar
  33. 33.
    Kondo K, Yao M, Yoshida M, et al.: Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002, 34:58–68.PubMedCrossRefGoogle Scholar
  34. 34.
    Smits KM, Schouten LJ, van Dijk BA, et al.: Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis. Clin Cancer Res 2008, 14:782–787.PubMedCrossRefGoogle Scholar
  35. 35.
    Gimenez-Bachs JM, Salinas-Sanchez AS, Sanchez-Sanchez F, et al.: Determination of vhl gene mutations in sporadic renal cell carcinoma. Eur Urol 2006, 49:1051–1057.PubMedCrossRefGoogle Scholar
  36. 36.
    Upton MP, Parker RA, Youmans A, et al.: Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005, 28:488–495.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim JH, Jung CW, Cho YH, et al.: Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 2005, 13:859–864.PubMedGoogle Scholar
  38. 38.
    Choueiri TK, Vaziri SA, Jaeger E, et al.: von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860–865; discussion 865–866.PubMedCrossRefGoogle Scholar
  39. 39.
    Rini BI, Jaeger E, Weinberg V, et al.: Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int 2006, 98:756–762.PubMedCrossRefGoogle Scholar
  40. 40.
    Gad S, Sultan-Amar V, Meric JB, et al.: Somatic von Hippel-Lindau (VHL) gene analysis and clinical outcome under antiangiogenic treatment in metastatic renal cell carcinoma: preliminary results. Targeted Oncol 2007, 2:3–6.CrossRefGoogle Scholar
  41. 41.
    Cho D, Signoretti S, Regan M, et al.: The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007, 13(2 Pt 2):758s–763s.PubMedCrossRefGoogle Scholar
  42. 42.
    Lynch TJ, Bell DW, Sordella R, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129–2139.PubMedCrossRefGoogle Scholar
  43. 43.
    Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69(Suppl 3):4–10.PubMedCrossRefGoogle Scholar
  44. 44.
    Miller K, Wang M, Gralow J, et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666–2676.PubMedCrossRefGoogle Scholar
  45. 45.
    Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.PubMedCrossRefGoogle Scholar
  46. 46.
    Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378–390.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2009

Authors and Affiliations

  1. 1.Lineberger Cancer CenterChapel HillUSA

Personalised recommendations